annual EBIT:
-$504.55M+$37.91M(+6.99%)Summary
- As of today (September 16, 2025), RARE annual earnings before interest & taxes is -$504.55 million, with the most recent change of +$37.91 million (+6.99%) on December 31, 2024.
- During the last 3 years, RARE annual EBIT has fallen by -$80.99 million (-19.12%).
- RARE annual EBIT is now -7569.02% below its all-time high of -$6.58 million, reached on December 31, 2011.
Performance
RARE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
-$107.89M+$35.05M(+24.52%)Summary
- As of today (September 16, 2025), RARE quarterly earnings before interest & taxes is -$107.89 million, with the most recent change of +$35.05 million (+24.52%) on June 30, 2025.
- Over the past year, RARE quarterly EBIT has increased by +$8.47 million (+7.28%).
Performance
RARE quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
-$505.09M+$8.47M(+1.65%)Summary
- As of today (September 16, 2025), RARE TTM earnings before interest & taxes is -$505.09 million, with the most recent change of +$8.47 million (+1.65%) on June 30, 2025.
- Over the past year, RARE TTM EBIT has increased by +$43.76 million (+7.97%).
Performance
RARE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RARE EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7.0% | +7.3% | +8.0% |
| 3 y3 years | -19.1% | +23.8% | -7.3% |
| 5 y5 years | -26.7% | -71.1% | -27.5% |
RARE EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -19.1% | +23.4% | at high | +52.1% | -7.3% | +24.9% |
| 5 y | 5-year | -231.8% | +23.4% | -114.4% | +52.1% | -66.8% | +24.9% |
| alltime | all time | -7569.0% | +23.4% | <-9999.0% | +52.1% | <-9999.0% | +24.9% |
RARE EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$107.89M(-24.5%) | -$505.09M(-1.6%) |
| Mar 2025 | - | -$142.94M(+16.9%) | -$513.57M(-4.2%) |
| Dec 2024 | -$504.55M(-7.0%) | -$122.28M(-7.4%) | -$535.97M(+0.0%) |
| Sep 2024 | - | -$131.99M(+13.4%) | -$535.74M(-2.4%) |
| Jun 2024 | - | -$116.36M(-29.6%) | -$548.85M(-5.4%) |
| Mar 2024 | - | -$165.35M(+35.5%) | -$580.45M(+2.0%) |
| Dec 2023 | -$542.46M(-17.6%) | -$122.05M(-15.9%) | -$569.21M(-4.0%) |
| Sep 2023 | - | -$145.10M(-1.9%) | -$592.79M(-11.9%) |
| Jun 2023 | - | -$147.96M(-4.0%) | -$672.76M(+1.0%) |
| Mar 2023 | - | -$154.10M(+5.8%) | -$666.39M(+2.7%) |
| Dec 2022 | -$658.71M(+55.5%) | -$145.63M(-35.3%) | -$648.92M(+7.1%) |
| Sep 2022 | - | -$225.07M(+59.0%) | -$605.86M(+28.7%) |
| Jun 2022 | - | -$141.59M(+3.6%) | -$470.62M(+14.3%) |
| Mar 2022 | - | -$136.63M(+33.2%) | -$411.80M(+7.9%) |
| Dec 2021 | -$423.56M(+178.5%) | -$102.56M(+14.2%) | -$381.74M(+5.4%) |
| Sep 2021 | - | -$89.83M(+8.5%) | -$362.05M(+12.3%) |
| Jun 2021 | - | -$82.78M(-22.3%) | -$322.54M(+6.5%) |
| Mar 2021 | - | -$106.57M(+28.6%) | -$302.82M(-4.4%) |
| Dec 2020 | -$152.07M(-61.8%) | -$82.88M(+64.7%) | -$316.92M(-3.5%) |
| Sep 2020 | - | -$50.31M(-20.2%) | -$328.49M(-17.1%) |
| Jun 2020 | - | -$63.05M(-47.7%) | -$396.20M(-11.1%) |
| Mar 2020 | - | -$120.67M(+27.8%) | -$445.62M(+5.1%) |
| Dec 2019 | -$398.31M(+102.1%) | -$94.45M(-20.0%) | -$424.17M(+1.0%) |
| Sep 2019 | - | -$118.03M(+4.9%) | -$420.06M(+7.2%) |
| Jun 2019 | - | -$112.47M(+13.4%) | -$391.67M(+4.7%) |
| Mar 2019 | - | -$99.21M(+9.8%) | -$374.10M(+0.7%) |
| Dec 2018 | -$197.10M | -$90.34M(+0.8%) | -$371.37M(-0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$89.65M(-5.5%) | -$371.87M(+1.6%) |
| Jun 2018 | - | -$94.90M(-1.6%) | -$365.93M(+4.7%) |
| Mar 2018 | - | -$96.49M(+6.2%) | -$349.48M(+8.2%) |
| Dec 2017 | -$318.34M(+28.4%) | -$90.83M(+8.5%) | -$322.94M(+6.7%) |
| Sep 2017 | - | -$83.71M(+6.7%) | -$302.66M(+6.3%) |
| Jun 2017 | - | -$78.44M(+12.1%) | -$284.73M(+7.7%) |
| Mar 2017 | - | -$69.95M(-0.8%) | -$264.34M(+6.6%) |
| Dec 2016 | -$248.01M(+67.9%) | -$70.55M(+7.2%) | -$248.01M(+6.2%) |
| Sep 2016 | - | -$65.78M(+13.3%) | -$233.62M(+12.4%) |
| Jun 2016 | - | -$58.05M(+8.3%) | -$207.77M(+15.5%) |
| Mar 2016 | - | -$53.62M(-4.5%) | -$179.86M(+21.7%) |
| Dec 2015 | -$147.74M(+160.2%) | -$56.16M(+40.6%) | -$147.74M(+36.1%) |
| Sep 2015 | - | -$39.94M(+32.5%) | -$108.52M(+28.5%) |
| Jun 2015 | - | -$30.14M(+40.2%) | -$84.42M(+24.3%) |
| Mar 2015 | - | -$21.50M(+26.9%) | -$67.94M(+19.7%) |
| Dec 2014 | -$56.78M(+75.9%) | -$16.94M(+7.0%) | -$56.78M(+15.0%) |
| Sep 2014 | - | -$15.84M(+15.9%) | -$49.36M(+19.6%) |
| Jun 2014 | - | -$13.66M(+32.1%) | -$41.29M(+49.5%) |
| Mar 2014 | - | -$10.34M(+8.5%) | -$27.63M(+14.9%) |
| Dec 2013 | -$32.28M(+101.9%) | -$9.53M(+22.7%) | -$24.03M(+25.3%) |
| Sep 2013 | - | -$7.76M(<-9900.0%) | -$19.19M(+19.4%) |
| Jun 2013 | - | $0.00(-100.0%) | -$16.07M(0.0%) |
| Mar 2013 | - | -$6.75M(+44.2%) | -$16.07M(+72.4%) |
| Dec 2012 | -$15.98M(+143.0%) | -$4.68M(+0.8%) | -$9.32M(+100.8%) |
| Sep 2012 | - | -$4.64M(<-9900.0%) | -$4.64M(<-9900.0%) |
| Jun 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2012 | - | $0.00 | $0.00 |
| Dec 2011 | -$6.58M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual earnings before interest & taxes?
- What is the all time high annual EBIT for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual EBIT year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly EBIT year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. TTM EBIT year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual earnings before interest & taxes?
The current annual EBIT of RARE is -$504.55M
What is the all time high annual EBIT for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual earnings before interest & taxes is -$6.58M
What is Ultragenyx Pharmaceutical Inc. annual EBIT year-on-year change?
Over the past year, RARE annual earnings before interest & taxes has changed by +$37.91M (+6.99%)
What is Ultragenyx Pharmaceutical Inc. quarterly earnings before interest & taxes?
The current quarterly EBIT of RARE is -$107.89M
What is the all time high quarterly EBIT for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly earnings before interest & taxes is $0.00
What is Ultragenyx Pharmaceutical Inc. quarterly EBIT year-on-year change?
Over the past year, RARE quarterly earnings before interest & taxes has changed by +$8.47M (+7.28%)
What is Ultragenyx Pharmaceutical Inc. TTM earnings before interest & taxes?
The current TTM EBIT of RARE is -$505.09M
What is the all time high TTM EBIT for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high TTM earnings before interest & taxes is $0.00
What is Ultragenyx Pharmaceutical Inc. TTM EBIT year-on-year change?
Over the past year, RARE TTM earnings before interest & taxes has changed by +$43.76M (+7.97%)